TrialOral oncology2019

Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.

Nabil F Saba et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.